Molecular and Cellular Biochemistry

, Volume 350, Issue 1–2, pp 127–134 | Cite as

Characterizing the novel protein p33MONOX



The novel protein p33MONOX (p33Monooxygenase) was over-expressed in neuroblastoma cells demonstrating its inhibitory effect on the phosphorylation of the App (amyloid precursor protein) and Bcl2 (B-cell lymphoma 2) proteins but mediating higher activation of Mapk1/3 (mitogen-activated protein kinase 1/3). We employed a variety of cell biology techniques to show the localization of p33MONOX to the cytoplasm of pyramidal neurons in the mouse brain hippocampus. We also carried out a yeast-two-hybrid screening plus co-immunoprecipitation and bio-informatics to determine COBRA1 (cofactor of BRCA1 (breast cancer type 1)), NOL12 (nucleolar protein 12), and PRNP (prion protein) as p33MONOX-interacting proteins. Bio-computational analyses revealed a flavine-containing monooxygenase (FMO)-1 motif, thus linking p33MONOX to a group of previously characterized proteins, the MICALs (molecule interacting with CasL). Concluding, p33MONOX might regulate pre- and post-transcriptional control of dynamic processes related to growth cone guidance.


Alzheimer’s disease Apoptosis Neurodegeneration 



This study was supported by an A*STAR grant (BMRC/04/1/22/19/360) to K.H. We thank Ms H.J. Tang and S. Yusof (both from the School of Biological Sciences, Nanyang Technical University) for technical assistance. We are particularly grateful to Prof. Dr. R. Li (Department of Molecular Medicine, Institute of Biotechnology, The University of Texas Health Science Center, 15355 Lambda Drive, San Antonio, TX, 78245-3207, USA) for providing us the anti-COBRA1 antibody.

Supplementary material

11010_2010_690_MOESM1_ESM.doc (158 kb)
Supplementary data associated with this article can be found, in the online version, at (DOC 155 kb)


  1. 1.
    Welsh KA, Butters N, Hughes JP, Mohs RC, Heyman A (1992) Detection and staging of dementia in Alzheimer’s disease. Use of the neuropsychological measures developed for the Consortium to Establish a Registry for Alzheimer’s Disease. Arch Neurol 49:448–452PubMedGoogle Scholar
  2. 2.
    Terry RD, Masliah E, Salmon DP, Butters N, DeTeresa R, Hill R, Hansen LA, Katzman R (1991) Physical basis of cognitive alterations in Alzheimer’s disease: synapse loss is the major correlate of cognitive impairment. Ann Neurol 30:572–580PubMedCrossRefGoogle Scholar
  3. 3.
    Heese K, Akatsu H (2006) Alzheimer’s disease—an interactive perspective. Curr Alzheimer Res 3:109–121PubMedCrossRefGoogle Scholar
  4. 4.
    Mattson MP (2004) Pathways towards and away from Alzheimer’s disease. Nature 430:631–639PubMedCrossRefGoogle Scholar
  5. 5.
    Selkoe DJ, Schenk D (2003) Alzheimer’s disease: molecular understanding predicts amyloid-based therapeutics. Annu Rev Pharmacol Toxicol 43:545–584PubMedCrossRefGoogle Scholar
  6. 6.
    Butterfield DA (2002) Amyloid beta-peptide (1-42)-induced oxidative stress and neurotoxicity: implications for neurodegeneration in Alzheimer’s disease brain. A review. Free Radic Res 36:1307–1313PubMedCrossRefGoogle Scholar
  7. 7.
    Butterfield DA, Castegna A, Lauderback CM, Drake J (2002) Evidence that amyloid beta-peptide-induced lipid peroxidation and its sequelae in Alzheimer’s disease brain contribute to neuronal death. Neurobiol Aging 23:655–664PubMedCrossRefGoogle Scholar
  8. 8.
    Pappolla MA, Chyan YJ, Omar RA, Hsiao K, Perry G, Smith MA, Bozner P (1998) Evidence of oxidative stress and in vivo neurotoxicity of beta-amyloid in a transgenic mouse model of Alzheimer’s disease: a chronic oxidative paradigm for testing antioxidant therapies in vivo. Am J Pathol 152:871–877PubMedGoogle Scholar
  9. 9.
    Yokota T, Mishra M, Akatsu H, Tani Y, Miyauchi T, Yamamoto T, Kosaka K, Nagai Y, Sawada T, Heese K (2006) Brain site-specific gene expression analysis in Alzheimer’s disease patients. Eur J Clin Invest 36:820–830PubMedCrossRefGoogle Scholar
  10. 10.
    Heese K, Yamada T, Akatsu H, Yamamoto T, Kosaka K, Nagai Y, Sawada T (2004) Characterizing the new transcription regulator protein p60TRP. J Cell Biochem 91:1030–1042PubMedCrossRefGoogle Scholar
  11. 11.
    Nehar S, Mishra M, Heese K (2009) Identification and characterisation of the novel amyloid-beta peptide-induced protein p17. FEBS Lett 583:3247–3253PubMedCrossRefGoogle Scholar
  12. 12.
    Massey V (1995) Introduction: flavoprotein structure and mechanism. FASEB J 9:473–475PubMedGoogle Scholar
  13. 13.
    Yeung CK, Lang DH, Thummel KE, Rettie AE (2000) Immunoquantitation of FMO1 in human liver, kidney, and intestine. Drug Metab Dispos 28:1107–1111PubMedGoogle Scholar
  14. 14.
    Ziegler DM (1990) Flavin-containing monooxygenases: enzymes adapted for multisubstrate specificity. Trends Pharmacol Sci 11:321–324PubMedCrossRefGoogle Scholar
  15. 15.
    Massey V (1994) Activation of molecular oxygen by flavins and flavoproteins. J Biol Chem 269:22459–22462PubMedGoogle Scholar
  16. 16.
    Lee MS, Kao SC, Lemere CA, Xia W, Tseng HC, Zhou Y, Neve R, Ahlijanian MK, Tsai LH (2003) APP processing is regulated by cytoplasmic phosphorylation. J Cell Biol 163:83–95PubMedCrossRefGoogle Scholar
  17. 17.
    Ito T, Deng X, Carr B, May WS (1997) Bcl-2 phosphorylation required for anti-apoptosis function. J Biol Chem 272:11671–11673PubMedCrossRefGoogle Scholar
  18. 18.
    Deng X, Ito T, Carr B, Mumby M, May WS Jr (1998) Reversible phosphorylation of Bcl2 following interleukin 3 or bryostatin 1 is mediated by direct interaction with protein phosphatase 2A. J Biol Chem 273:34157–34163PubMedCrossRefGoogle Scholar
  19. 19.
    Deng X, Gao F, Flagg T, May WS Jr (2004) Mono- and multisite phosphorylation enhances Bcl2’s antiapoptotic function and inhibition of cell cycle entry functions. Proc Natl Acad Sci USA 101:153–158PubMedCrossRefGoogle Scholar
  20. 20.
    Yamamoto K, Ichijo H, Korsmeyer SJ (1999) BCL-2 is phosphorylated and inactivated by an ASK1/Jun N-terminal protein kinase pathway normally activated at G(2)/M. Mol Cell Biol 19:8469–8478PubMedGoogle Scholar
  21. 21.
    Chang BS, Minn AJ, Muchmore SW, Fesik SW, Thompson CB (1997) Identification of a novel regulatory domain in Bcl-X(L) and Bcl-2. EMBO J 16:968–977PubMedCrossRefGoogle Scholar
  22. 22.
    Liu XA, Liao K, Liu R, Wang HH, Zhang Y, Zhang Q, Wang Q, Li HL, Tian Q, Wang JZ (2010) Tau dephosphorylation potentiates apoptosis by mechanisms involving a failed dephosphorylation/activation of Bcl-2. J Alzheimer’s Dis 19:953–962Google Scholar
  23. 23.
    Kholodenko BN (2007) Untangling the signalling wires. Nat Cell Biol 9:247–249PubMedCrossRefGoogle Scholar
  24. 24.
    McChesney PA, Aiyar SE, Lee OJ, Zaika A, Moskaluk C, Li R, El-Rifai W (2006) Cofactor of BRCA1: a novel transcription factor regulator in upper gastrointestinal adenocarcinomas. Cancer Res 66:1346–1353PubMedCrossRefGoogle Scholar
  25. 25.
    Kramer PR, Wray S (2001) Nasal embryonic LHRH factor (NELF) expression within the CNS and PNS of the rodent. Brain Res Gene Expr Patterns 1:23–26PubMedCrossRefGoogle Scholar
  26. 26.
    Kramer PR, Wray S (2000) Novel gene expressed in nasal region influences outgrowth of olfactory axons and migration of luteinizing hormone-releasing hormone (LHRH) neurons. Genes Dev 14:1824–1834PubMedGoogle Scholar
  27. 27.
    Sun J, Blair AL, Aiyar SE, Li R (2007) Cofactor of BRCA1 modulates androgen-dependent transcription and alternative splicing. J Steroid Biochem Mol Biol 107:131–139PubMedCrossRefGoogle Scholar
  28. 28.
    Narita T, Yamaguchi Y, Yano K, Sugimoto S, Chanarat S, Wada T, Kim DK, Hasegawa J, Omori M, Inukai N, Endoh M, Yamada T, Handa H (2003) Human transcription elongation factor NELF: identification of novel subunits and reconstitution of the functionally active complex. Mol Cell Biol 23:1863–1873PubMedCrossRefGoogle Scholar
  29. 29.
    Suzuki S, Kanno M, Fujiwara T, Sugiyama H, Yokoyama A, Takahashi H, Tanaka J (2006) Molecular cloning and characterization of Nop25, a novel nucleolar RNA binding protein, highly conserved in vertebrate species. Exp Cell Res 312:1031–1041PubMedCrossRefGoogle Scholar
  30. 30.
    Stelzl U, Worm U, Lalowski M, Haenig C, Brembeck FH, Goehler H, Stroedicke M, Zenkner M, Schoenherr A, Koeppen S, Timm J, Mintzlaff S, Abraham C, Bock N, Kietzmann S, Goedde A, Toksoz E, Droege A, Krobitsch S, Korn B, Birchmeier W, Lehrach H, Wanker EE (2005) A human protein–protein interaction network: a resource for annotating the proteome. Cell 122:957–968PubMedCrossRefGoogle Scholar
  31. 31.
    Juanes ME, Elvira G, Garcia-Grande A, Calero M, Gasset M (2009) Biosynthesis of prion protein nucleocytoplasmic isoforms by alternative initiation of translation. J Biol Chem 284:2787–2794PubMedCrossRefGoogle Scholar
  32. 32.
    Satoh J, Obayashi S, Misawa T, Sumiyoshi K, Oosumi K, Tabunoki H (2009) Protein microarray analysis identifies human cellular prion protein interactors. Neuropathol Appl Neurobiol 35:16–35PubMedCrossRefGoogle Scholar
  33. 33.
    Haigh CL, Lewis VA, Vella LJ, Masters CL, Hill AF, Lawson VA, Collins SJ (2009) PrPC-related signal transduction is influenced by copper, membrane integrity and the alpha cleavage site. Cell Res 19:1062–1078PubMedCrossRefGoogle Scholar
  34. 34.
    Haitina T, Lindblom J, Renstrom T, Fredriksson R (2006) Fourteen novel human members of mitochondrial solute carrier family 25 (SLC25) widely expressed in the central nervous system. Genomics 88:779–790PubMedCrossRefGoogle Scholar
  35. 35.
    Miao L, St Clair DK (2009) Regulation of superoxide dismutase genes: implications in disease. Free Radic Biol Med 47:344–356PubMedCrossRefGoogle Scholar
  36. 36.
    Lynn S, Huang EJ, Elchuri S, Naeemuddin M, Nishinaka Y, Yodoi J, Ferriero DM, Epstein CJ, Huang TT (2005) Selective neuronal vulnerability and inadequate stress response in superoxide dismutase mutant mice. Free Radic Biol Med 38:817–828PubMedCrossRefGoogle Scholar
  37. 37.
    Terman JR, Mao T, Pasterkamp RJ, Yu HH, Kolodkin AL (2002) MICALs, a family of conserved flavoprotein oxidoreductases, function in plexin-mediated axonal repulsion. Cell 109:887–900PubMedCrossRefGoogle Scholar
  38. 38.
    Massey V, Palmer G (1966) On the existence of spectrally distinct classes of flavoprotein semiquinones. A new method for the quantitative production of flavoprotein semiquinones. Biochemistry 5:3181–3189PubMedCrossRefGoogle Scholar
  39. 39.
    Ventura A, Pelicci PG (2002) Semaphorins: green light for redox signaling? Sci STKE 2002: pe44Google Scholar
  40. 40.
    Kamata H, Hirata H (1999) Redox regulation of cellular signalling. Cell Signal 11:1–14PubMedCrossRefGoogle Scholar
  41. 41.
    Finkel T (1998) Oxygen radicals and signaling. Curr Opin Cell Biol 10:248–253PubMedCrossRefGoogle Scholar
  42. 42.
    Meng TC, Fukada T, Tonks NK (2002) Reversible oxidation and inactivation of protein tyrosine phosphatases in vivo. Mol Cell 9:387–399PubMedCrossRefGoogle Scholar
  43. 43.
    Juurlink BH, Paterson PG (1998) Review of oxidative stress in brain and spinal cord injury: suggestions for pharmacological and nutritional management strategies. J Spinal Cord Med 21:309–334PubMedGoogle Scholar
  44. 44.
    Lovell MA, Ehmann WD, Butler SM, Markesbery WR (1995) Elevated thiobarbituric acid-reactive substances and antioxidant enzyme activity in the brain in Alzheimer’s disease. Neurology 45:1594–1601Google Scholar
  45. 45.
    Schuessel K, Leutner S, Cairns NJ, Muller WE, Eckert A (2004) Impact of gender on upregulation of antioxidant defence mechanisms in Alzheimer’s disease brain. J Neural Transm 111:1167–1182PubMedCrossRefGoogle Scholar
  46. 46.
    Nunomura A, Chiba S, Lippa CF, Cras P, Kalaria RN, Takeda A, Honda K, Smith MA, Perry G (2004) Neuronal RNA oxidation is a prominent feature of familial Alzheimer’s disease. Neurobiol Dis 17:108–113PubMedCrossRefGoogle Scholar
  47. 47.
    Hirai K, Aliev G, Nunomura A, Fujioka H, Russell RL, Atwood CS, Johnson AB, Kress Y, Vinters HV, Tabaton M, Shimohama S, Cash AD, Siedlak SL, Harris PL, Jones PK, Petersen RB, Perry G, Smith MA (2001) Mitochondrial abnormalities in Alzheimer’s disease. J Neurosci 21:3017–3023PubMedGoogle Scholar
  48. 48.
    Behl C (2005) Oxidative stress in Alzheimer’s disease: implications for prevention and therapy. Subcell Biochem 38:65–78PubMedCrossRefGoogle Scholar
  49. 49.
    Reddy PH (2006) Amyloid precursor protein-mediated free radicals and oxidative damage: implications for the development and progression of Alzheimer’s disease. J Neurochem 96:1–13PubMedCrossRefGoogle Scholar
  50. 50.
    Premkumar DR, Smith MA, Richey PL, Petersen RB, Castellani R, Kutty RK, Wiggert B, Perry G, Kalaria RN (1995) Induction of heme oxygenase-1 mRNA and protein in neocortex and cerebral vessels in Alzheimer’s disease. J Neurochem 65:1399–1402PubMedCrossRefGoogle Scholar
  51. 51.
    Schipper HM, Cisse S, Stopa EG (1995) Expression of heme oxygenase-1 in the senescent and Alzheimer-diseased brain. Ann Neurol 37:758–768PubMedCrossRefGoogle Scholar
  52. 52.
    Smith MA, Kutty RK, Richey PL, Yan SD, Stern D, Chader GJ, Wiggert B, Petersen RB, Perry G (1994) Heme oxygenase-1 is associated with the neurofibrillary pathology of Alzheimer’s disease. Am J Pathol 145:42–47PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC. 2010

Authors and Affiliations

  1. 1.Department of Molecular and Cell Biology, School of Biological Sciences, College of ScienceNanyang Technological UniversitySingaporeSingapore
  2. 2.Medical Center for Translational ResearchOsaka University HospitalSuita, OsakaJapan

Personalised recommendations